|
Nuclear BCL10 expression
|
---|
Total (N)
|
Negative
|
Positive
|
p-value
|
---|
Number
|
136
|
78 (57.4%)
|
58 (42.6%)
| |
Age
| | | |
0.837†
|
Median
|
59.0
|
58.0
|
61.0
| |
Range
|
27–82
|
35–82
|
27–76
| |
Sex
| | | |
0.102‡
|
Men
|
83 (61.0%)
|
43 (55.1%)
|
40 (69.0%)
| |
Women
|
53 (39.0%)
|
35 (44.9%)
|
18 (31.0%)
| |
Smoking
| | | |
0.262‡
|
No
|
87 (64.0%)
|
53 (67.9%)
|
34 (58.6%)
| |
Yes
|
49 (36/0%)
|
25 (32.1%)
|
24 (41.4%)
| |
Alcohol
| | | |
0.937‡
|
No
|
98 (72.1%)
|
56 (71.8%)
|
42 (72.4%)
| |
Yes
|
38 (27.9%)
|
22 (28.2%)
|
16 (27.6%)
| |
Stage
| | | |
0.743§
|
Recurrent
|
37 (27.2%)
|
23 (29.5%)
|
14 (24.1%)
| |
Stage IIIB
|
19 (14.0%)
|
9 (11.5%)
|
10 (17.2%)
| |
Stage IV
|
80 (58.8%)
|
46 (59.0%)
|
34 (58.6%)
| |
Metastases
| | | |
0.667§
|
Peritoneal
|
12 (8.8%)
|
7 (9.0%)
|
5 (9.6%)
| |
Liver
|
83 (61.0%)
|
47 (60.2%)
|
36 (62.1%)
| |
Other sitesa
|
23 (16.9%)
|
12 (15.4%)
|
11 (19.0%)
| |
Regional LNs
|
18 (13.2%)
|
12 (15.4%)
|
6 (10.3%)
| |
Chemotherapy
| | | |
0.306‡
|
Gem-alone
|
44 (32.4%)
|
28 (35.9%)
|
16 (27.6%)
| |
Gem-based
|
92 (67.6%)
|
50 (61.1%)
|
42 (72.4%)
| |
Response
| | | |
0.423§
|
CR + PR
|
11 (8.1%)
|
6 (7.7%)
|
5 (8.6%)
| |
SD + PD
|
85 (62.5%)
|
51 (65.4%)
|
34 (58.6%)
| |
NA
|
40 (29.4%)
|
21 (26.9%)
|
19 (32.8%)
| |
NF-κB expressionb
| | | |
< 0.001‡
|
Negative
|
58 (61.1%)
|
49 (84.5%)
|
9 (24.3%)
| |
Positive
|
37 (38.9%)
|
9 (15.5%)
|
28 (75.7%)
| |
- PDAC pancreatic ductal adenocarcinoma, N number, LNs lymph nodes, Gem gemcitabine, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, NA non-analyses or difficult to assess the response
- aOther sites: included extra-liver lesions, such as lung, adrenal gland metastases
- bNF-κB expression was examined in tumor cells of selected 95 cases of PDAC
- †P values (2-sided) were calculated using the Student t test
- ‡P values (2-sided) were calculated using the Χ2 test or the Fisher exact test
- §P values (2-sided) were calculated using 1-way analysis of variance